Jinwon Life Sciences Publishes Usefulness of DNA Vaccine Platform Development in International Scientific Journal

GeneOne Life Science announced on the 26th that it has published a review on the development status of DNA vaccines during the COVID-19 pandemic and the strengths of the DNA vaccine development platform as a response strategy for future emerging infectious diseases in the international academic journal Vaccines.

The title of the paper is "DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond." It was based on a presentation by Dr. Joel Maslow, Chief Medical Officer of GeneOne Life Science, who was invited as an authority in the field of DNA vaccines to the international conference "Vaccines and Vaccination During and Post Covid Pandemics" in December last year.

In the paper, the GeneOne Life Science research team conducted a comparative analysis of the efficacy and DNA vaccine delivery devices used in COVID-19 preventive DNA vaccines that have progressed to Phase 2 clinical trials or beyond, including ZyCoV-D, the world's first DNA COVID-19 vaccine approved under emergency authorization by the Indian government.

DNA vaccines are attracting attention as next-generation vaccine technology for responding to emerging infectious diseases due to their advantages such as proven safety through long-term research, rapid development capability, ease of mass production, and the ability to simultaneously induce antibody and cellular immune responses.

GLS-5310, a COVID-19 DNA vaccine developed by GeneOne Life Science, is currently undergoing Phase 1/2a clinical trials in Korea and booster shot clinical studies in the United States. The Phase 1 clinical trial results published in the International Journal of Infectious Diseases demonstrated GLS-5310's excellent tolerability, safety, and stable immune response and efficacy lasting for one year. The suction-based intradermal delivery device GeneDerm used for GLS-5310 vaccination showed superior efficacy compared to other delivery devices, confirming its potential as a next-generation medical device for DNA vaccine administration.

Young-Geun Park, CEO of GeneOne Life Science, emphasized, "As the risk of pandemics remains even after the COVID-19 endemic phase, the significance of developing a DNA vaccine platform as an effective response strategy for future emerging infectious disease pandemics, including COVID-19, is very great. Through our company's capabilities, which have led the development of nucleic acid-based vaccines for emerging infectious diseases, and our independently developed ideal DNA delivery platform, the suction-based intradermal delivery device GeneDerm, we can contribute to efficiently responding to future pandemics."